Purple Biotech Ltd.
3.64
-0.14 (-3.70%)
At close: Jan 14, 2025, 3:59 PM
3.62
-0.55%
Pre-market Jan 15, 2025, 04:03 AM EST
undefined%
Bid 3.54
Market Cap 9.41M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -8.1
PE Ratio (ttm) -0.45
Forward PE n/a
Analyst Buy
Ask 3.74
Volume 44,266
Avg. Volume (20D) 954,573
Open 3.68
Previous Close 3.78
Day's Range 3.55 - 3.87
52-Week Range 2.00 - 20.60
Beta undefined

About PPBT

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer and panc...

Industry Biotechnology
Sector Healthcare
IPO Date Nov 20, 2015
Employees 20
Stock Exchange NASDAQ
Ticker Symbol PPBT

Analyst Forecast

According to 2 analyst ratings, the average rating for PPBT stock is "Buy." The 12-month stock price forecast is $126.5, which is an increase of 3375.27% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts
1 month ago · Source
-21.79%
Purple Biotech shares are trading lower after the ... Unlock content with Pro Subscription
1 month ago · Source
+150%
Purple Biotech shares are trading higher after the company announced final results from the randomized Phase 2 study of its lead oncology drug, CM24 in patients with pancreatic ductal adenocarcinoma.